Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Kirin-do: Double-digit Increases in Sales, Profits
April 16, 2001
- Criteria for Disclosure, Non-disclosure Published
April 16, 2001
- MEDICAL DEVICE NEWS IN BRIEF
April 16, 2001
- Hitachi, Myriad, Oracle, Friedli to Tie Up in Proteomics
April 16, 2001
- JPA Leader Comments on New Deregulation Promotion Plan
April 16, 2001
- Sankyo to Be Aggressive in Genomic Drug Discovery: Dr Hiraoka
April 16, 2001
- Toyama to Exclusively Market YP-14 Jointly Developed with Taiho
April 16, 2001
- Review of NHI Price System Included in New Deregulation Plan
April 16, 2001
- Daiichi, Medtronic Codevelop Intrathecal Baclofen Therapy
April 16, 2001
- Novartis to Double Sales in 5 Years in Transplantation, Immunology, Cancer
April 16, 2001
- REGULATORY NEWS IN BRIEF -1-
April 16, 2001
- Kirin Brewery to Survive by Focusing on Cancer, Nephrology, Allergy/Immunology
April 16, 2001
- The Cues in Pharma Communication (2)
April 16, 2001
- Quintiles to Double Its Sales in Japan in FY2001
April 16, 2001
- REGULATORY NEWS IN BRIEF -2-
April 16, 2001
- Immediate PMS of Mobic Undertaken by Nippon Boehringer Ingelheim, Daiichi
April 16, 2001
- Bungyo Rate Exceeds 40%for Two Consecutive Months
April 16, 2001
- Developing Anti-AIDS Vaccine to Be Given Top Priority: Merck Company Foundation
April 16, 2001
- Reform of Medical Education Proposed to Promote Patient-centered Healthcare
April 16, 2001
- BUSINESS NEWS IN BRIEF -2-
April 16, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…